Cabozantinib,Nivolumab,Ipilimumab,Pembrolizumab
Exelixis,bms,merck
['melsm', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'cosmic-313']
to have the renowned reference #s1801 study in this way as one of the most impactful at #esmo22 is an honor!! he is humbly omitting his triplet regimen in #cosmic-313 which had a strong signal in intermediate-risk rcc #neoadjuvant #melsm 
SWOG Melanoma Chair, Med Onc at MD Anderson Cancer Center.  Tweets are my own.